Back to Stakeholders

Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.

Reimbursement & Market Access Snapshot

Health Economists

Service Model

Public Payer / National Coverage Authority

Jurisdiction

National

Coverage

1 country

Last Verified

Apr 8, 2026

Focus Areas

HTA Evidence AppraisalCost-Effectiveness ModelingBudget Impact AnalysisCoverage Policy DesignFormulary & Access Criteria

Evidence Requirements

Clinical Efficacy EndpointsComparative EffectivenessCost-EffectivenessBudget ImpactPatient-Reported Outcomes

Market Access Notes

PBAC forms recommendations underpinning PBS listing decisions and publishes medicine-status updates that include esketamine-related records.

Verification

Verified

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement Status

Active

Primary Access Link

Public Sector Governance Snapshot

Health Technology Assessment Agencies

Authority Type

Health Technology Assessment Agency

Jurisdiction

National

Coverage

1 country

Framework Status

Active

Function Areas

HTA Evidence AppraisalHealth System ImplementationClinical Guidance Publication

Governance Notes

Wave 5 L3 completion pass for Pharmaceutical Benefits Advisory Committee (PBAC).

Verification

Verified

Psychedelic Engagement

Psychedelic-Adjacent Focus

Last Verified

Apr 16, 2026

Verification Notes

PBAC process and PBS esketamine listing support adjacent psychedelic-governance categorization.

Primary Governance Link

Policy Instruments

Esketamine PBS listing assessment

HTA Recommendation / Decision

PBS esketamine medicine page

Quick Facts

Website
Visit